MedinCell (MEDCL) Stock Overview
A clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
MEDCL Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
MedinCell S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €27.18 |
| 52 Week High | €39.68 |
| 52 Week Low | €15.00 |
| Beta | 1 |
| 1 Month Change | 17.36% |
| 3 Month Change | 10.13% |
| 1 Year Change | 66.54% |
| 3 Year Change | 293.91% |
| 5 Year Change | 138.42% |
| Change since IPO | 269.80% |
Recent News & Updates
Narrative Update • Apr 27
MEDCL: Long-Acting Schizophrenia Injection Progress Will Drive Future Upside
The analyst price target for MedinCell has increased slightly from €33.85 to €34.28 as analysts adjust their assumptions for revenue growth, profit margins and future P/E expectations. What's in the News MedinCell and Teva Pharmaceuticals reported that the U.S. FDA accepted the New Drug Application for TEV-'749, an investigational once monthly olanzapine extended release injectable suspension for adults with schizophrenia, using MedinCell's SteadyTeq copolymer technology (Key Developments).Narrative Update • Apr 10
MEDCL: Schizophrenia Injection And 2026 Sales Outlook Will Drive Upside
Narrative Update on MedinCell The analyst price target for MedinCell remains steady at €33.85, as analysts keep their fair value view, discount rate, revenue growth outlook and profit margin assumptions essentially unchanged. What's in the News MedinCell completed a follow on equity offering of 2,370,000 ordinary shares, raising €48.2295 million at a price of €20.35 per share, via a subsequent direct listing (Key Developments).Narrative Update • Mar 27
MEDCL: 2026 Revenue Ramp And Schizophrenia Launch Will Drive Upside
Analysts now set their price target for MedinCell at €33.85, slightly below the prior €34.23. This reflects updated assumptions on long term profit margins and a higher future P/E multiple in their models.Narrative Update • Mar 11
MEDCL: 2026 Sales Outlook And New Schizophrenia Therapy Will Drive Upside
Analysts have trimmed their price target on MedinCell by about €1.04 to reflect an updated fair value of €34.23, as they factor in revised assumptions around revenue growth, profit margins and future P/E expectations. What's in the News MedinCell completed a follow on equity offering of ordinary shares, raising about €48.23 million by issuing 2,370,000 shares at €20.35 per share, via a subsequent direct listing (Key Developments).Recent updates
Narrative Update • Apr 27
MEDCL: Long-Acting Schizophrenia Injection Progress Will Drive Future Upside
The analyst price target for MedinCell has increased slightly from €33.85 to €34.28 as analysts adjust their assumptions for revenue growth, profit margins and future P/E expectations. What's in the News MedinCell and Teva Pharmaceuticals reported that the U.S. FDA accepted the New Drug Application for TEV-'749, an investigational once monthly olanzapine extended release injectable suspension for adults with schizophrenia, using MedinCell's SteadyTeq copolymer technology (Key Developments).Narrative Update • Apr 10
MEDCL: Schizophrenia Injection And 2026 Sales Outlook Will Drive Upside
Narrative Update on MedinCell The analyst price target for MedinCell remains steady at €33.85, as analysts keep their fair value view, discount rate, revenue growth outlook and profit margin assumptions essentially unchanged. What's in the News MedinCell completed a follow on equity offering of 2,370,000 ordinary shares, raising €48.2295 million at a price of €20.35 per share, via a subsequent direct listing (Key Developments).Narrative Update • Mar 27
MEDCL: 2026 Revenue Ramp And Schizophrenia Launch Will Drive Upside
Analysts now set their price target for MedinCell at €33.85, slightly below the prior €34.23. This reflects updated assumptions on long term profit margins and a higher future P/E multiple in their models.Narrative Update • Mar 11
MEDCL: 2026 Sales Outlook And New Schizophrenia Therapy Will Drive Upside
Analysts have trimmed their price target on MedinCell by about €1.04 to reflect an updated fair value of €34.23, as they factor in revised assumptions around revenue growth, profit margins and future P/E expectations. What's in the News MedinCell completed a follow on equity offering of ordinary shares, raising about €48.23 million by issuing 2,370,000 shares at €20.35 per share, via a subsequent direct listing (Key Developments).Narrative Update • Feb 25
MEDCL: 2026 Revenue Outlook And New Schizophrenia Drug Will Support Upside
Analysts have kept their price target for MedinCell steady at €35.26, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E in their latest update. What's in the News Teva Pharmaceuticals and MedinCell announced that the U.S. FDA has accepted the New Drug Application for TEV-'749, an olanzapine extended-release injectable suspension for adult schizophrenia treatment, using MedinCell’s SteadyTeq copolymer technology for controlled sustained drug release (Key Developments).Narrative Update • Feb 09
MEDCL: 2026 Revenue Guidance Will Support Upside As Profitability Outlook Strengthens
Analysts have trimmed their price target on MedinCell to about €35.26 from roughly €36.16, citing slightly higher discount rate assumptions, modestly softer revenue growth expectations of around 61.5% and a lower projected profit margin of about 70.3%, partly offset by a higher assumed future P/E multiple near 14.5x. What's in the News MedinCell issued revenue guidance for 2026, with expected net sales in a range of $250 million to $280 million.Narrative Update • Jan 25
MEDCL: Index Inclusion Will Support Upside As Profitability Outlook Strengthens
Analysts have raised their price target on MedinCell to €36.16 from €35.10, citing updated assumptions that incorporate a higher projected profit margin along with a lower future P/E multiple in their models. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, which covers liquid small-cap companies across 23 developed markets, increasing its visibility to global equity investors who track MSCI benchmarks (Key Developments).Narrative Update • Jan 11
MEDCL: Index Inclusion Will Support Future Upside Potential
Analysts have raised their price target on MedinCell to €35.10. The latest update reflects adjusted expectations around revenue growth, profit margins and future P/E assumptions.Narrative Update • Dec 19
MEDCL: Index Inclusion And New FDA Label Will Drive Upside Potential
Analysts have marginally raised their price target on MedinCell from €34.39 to €35.10, citing slightly stronger long term revenue growth expectations that more than offset a modestly lower projected profit margin and a reduced future P E multiple. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, increasing its visibility among global institutional and index-tracking investors from 24 November 2025 (company announcement).Narrative Update • Dec 05
MEDCL: Future Index Inclusion Will Drive Visibility And Earnings Upside Potential
Analysts have modestly reduced their price target for MedinCell by approximately $0.49 per share, reflecting tempered expectations for revenue growth, partially offset by improved projected profit margins and slightly lower future valuation multiples. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, boosting its visibility among global institutional investors and index-tracking funds, effective at the opening of trading on 24 November 2025 (Client Announcement) The FDA has approved UZEDY, a once monthly, subcutaneous long acting risperidone injection using MedinCell’s SteadyTeq technology, for maintenance treatment of bipolar I disorder in adults, expanding its label beyond schizophrenia (Product Related Announcement) MedinCell plans to submit a New Drug Application in the US for Olanzapine LAI, a once monthly long acting injection for schizophrenia using its co polymer technology licensed to Teva, in the fourth quarter of 2025, following positive Phase 3 safety data (Product Related Announcement) UZEDY has received regulatory approval in South Korea and is showing strong commercial traction, with 2024 net sales of 117 million dollars and 95 million dollars already in the first half of 2025.Analysis Article • Dec 01
MedinCell S.A.'s (EPA:MEDCL) 27% Cheaper Price Remains In Tune With Revenues
MedinCell S.A. ( EPA:MEDCL ) shares have retraced a considerable 27% in the last month, reversing a fair amount of...Narrative Update • Nov 21
MEDCL: Index Inclusion Will Drive Increased Visibility And Market Confidence
Analysts have slightly reduced their fair value price target for MedinCell from $35.16 to $34.87, reflecting tempered expectations around revenue growth and profit margins. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, which may enhance visibility among institutional investors and index-tracking funds.Narrative Update • Nov 06
MEDCL: Profit Margins Are Expected To Improve Significantly With Recent FDA Approval
Analysts have raised their price target for MedinCell from $31.16 to $35.16. This change reflects increased confidence in the company’s future profitability and outlook, even though there is a slightly higher discount rate and moderated revenue growth projections.Narrative Update • Oct 23
Analysts Lift MedinCell Price Target on Strong Revenue Outlook and Positive Regulatory Developments
Analysts have raised their price target for MedinCell from €26.90 to €31.16, citing improved revenue growth projections and favorable updates to future earnings expectations as key drivers for this upward revision. What's in the News FDA approves UZEDY, a once-monthly, long-acting risperidone injection, as monotherapy or adjunctive therapy for maintenance treatment of bipolar I disorder in adults.Narrative Update • Oct 09
Global Expansion And Extended Patents Will Unlock Future Opportunities
Analysts have raised their price target for MedinCell from $24.47 to $26.90, citing stronger fair value projections and underlying optimism in the company’s financial outlook. What's in the News MedinCell plans to submit a New Drug Application (NDA) for Olanzapine LAI, a once-monthly long-acting treatment for schizophrenia, in the US during the fourth quarter of 2025 (Key Developments).Narrative Update • Sep 25
Global Expansion And Extended Patents Will Unlock Future Opportunities
The upward revision in MedinCell's price target reflects a significant increase in consensus revenue growth forecasts coupled with a notable decline in the future P/E ratio, resulting in a new fair value estimate of €24.47. What's in the News UZEDY, a long-acting injectable risperidone for schizophrenia, received regulatory approval in South Korea and will be distributed by Teva Handok.Analysis Article • Sep 25
Why Investors Shouldn't Be Surprised By MedinCell S.A.'s (EPA:MEDCL) 30% Share Price Surge
The MedinCell S.A. ( EPA:MEDCL ) share price has done very well over the last month, posting an excellent gain of 30...New Narrative • Sep 05
Global Expansion And Extended Patents Will Unlock Future Opportunities
Key Takeaways Expansion of UZEDY and BEPO®-based programs, along with strong partnerships, underpin growth and reduce reliance on a single product. Extended patent protection and real-world value evidence support sustained pricing power and margin strength amid growing demand globally.Analysis Article • Jun 19
News Flash: Analysts Just Made A Substantial Upgrade To Their MedinCell S.A. (EPA:MEDCL) Forecasts
MedinCell S.A. ( EPA:MEDCL ) shareholders will have a reason to smile today, with the analysts making substantial...Analysis Article • Dec 25
Industry Analysts Just Made An Incredible Upgrade To Their MedinCell S.A. (EPA:MEDCL) Revenue Forecasts
MedinCell S.A. ( EPA:MEDCL ) shareholders will have a reason to smile today, with the analysts making substantial...Analysis Article • Jul 05
MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be
The latest analyst coverage could presage a bad day for MedinCell S.A. ( EPA:MEDCL ), with the analysts making...Analysis Article • Apr 26
Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%
Despite an already strong run, MedinCell S.A. ( EPA:MEDCL ) shares have been powering on, with a gain of 30% in the...Analysis Article • Jan 09
Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher
The MedinCell S.A. ( EPA:MEDCL ) share price has done very well over the last month, posting an excellent gain of 26...Analysis Article • Mar 02
The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On
MedinCell S.A. ( EPA:MEDCL ) shareholders might be concerned after seeing the share price drop 17% in the last month...Analysis Article • Jan 08
Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?
Every investor in MedinCell S.A. ( EPA:MEDCL ) should be aware of the most powerful shareholder groups. Large companies...Shareholder Returns
| MEDCL | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | -0.7% | 2.9% | 2.0% |
| 1Y | 66.5% | -10.6% | 1.3% |
Return vs Industry: MEDCL exceeded the French Pharmaceuticals industry which returned -10.6% over the past year.
Return vs Market: MEDCL exceeded the French Market which returned 1.3% over the past year.
Price Volatility
| MEDCL volatility | |
|---|---|
| MEDCL Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in FR Market | 10.6% |
| 10% least volatile stocks in FR Market | 3.0% |
Stable Share Price: MEDCL has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: MEDCL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 145 | Christophe Douat | www.medincell.com |
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder.
MedinCell S.A. Fundamentals Summary
| MEDCL fundamental statistics | |
|---|---|
| Market cap | €975.87m |
| Earnings (TTM) | -€19.95m |
| Revenue (TTM) | €32.44m |
30.1x
P/S Ratio-48.9x
P/E RatioIs MEDCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDCL income statement (TTM) | |
|---|---|
| Revenue | €32.44m |
| Cost of Revenue | €0 |
| Gross Profit | €32.44m |
| Other Expenses | €52.39m |
| Earnings | -€19.95m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Jun 16, 2026
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 100.00% |
| Net Profit Margin | -61.49% |
| Debt/Equity Ratio | -232.2% |
How did MEDCL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/24 16:13 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MedinCell S.A. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Seynnaeve | Degroof Petercam |
| Michael DiFiore | Evercore ISI |
| Raghuram Selvaraju | H.C. Wainwright & Co. |